Boston University-Raised Solx Will Leave The Nest With DeepLight Launch
This article was originally published in The Gray Sheet
Executive Summary
Solx plans to formally begin commercial operations when it launches the DeepLight glaucoma treatment system at the International Glaucoma Symposium in Cape Town, South Africa, March 30-April 2
You may also be interested in...
AMO Adds Glaucoma Device, Fills Cataract Line With $450 Mil. Pfizer Eye Unit
Advanced Medical Optics' purchase of Pfizer's surgical ophthalmology business bolsters its cataract surgery portfolio by adding viscoelastics and expanded intraocular lens (IOL) offerings
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.